This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Omnicell (OMCL) to Expand EnlivenHealth Division With New Buyout
by Zacks Equity Research
Omnicell's (OMCL) $82-million buyout of MarkeTouch Media is likely to expand its Advanced Services portfolio.
Quest Diagnostics (DGX) Rides on Test Sales, Base Volume Gain
by Zacks Equity Research
Quest Diagnostics (DGX) continues to benefit from rapidly increasing molecular diagnostic testing volumes, driven by the massive spread of the new COVID-19 variant.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) given the strength in the diagnostics business and notable acquisition deals.
Here's Why You Should Hold on to Myriad Genetics (MYGN) for Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.
Phirbo's (PAHC) Rising Costs, Currency Headwind Ail Growth
by Zacks Equity Research
Though Phirbo (PAHC) has raised prices on selective products, these increases do not fully compensate for the higher cost of freight and labor materials.
Here's Why You Should Hold on to National Vision (EYE) for Now
by Zacks Equity Research
Investors are optimistic about National Vision (EYE), given new store growth for America's Best and Eyeglass World brands.
Apollo Endosurgery, Inc. (APEN) Moves 7% Higher: Will This Strength Last?
by Zacks Equity Research
Apollo Endosurgery, Inc. (APEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why You Should Invest in Abbott (ABT) Stock Right Now
by Zacks Equity Research
Riding on current business growth and bullish near-term prospects, Abbott (ABT) is worth investing in for now.
Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strength in end markets and significant contribution from COVID-response related revenues are driving Thermo Fisher's (TMO) top line.
Omnicell (OMCL) Closes ReCept Holdings Acquisition Deal
by Zacks Equity Research
Omnicell's (OMCL) completed buyout of the renowned specialty pharmacy management services provider is likely to bolster its Advanced Services offering.
Neogen (NEOG) Q2 Earnings Lag Estimates, Revenues Surpass
by Zacks Equity Research
Robust segmental performance and contributions from StandGuard & Soleris product lines drove the top line for Neogen (NEOG) in the second quarter of fiscal 2022.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) strong sales in its mask product offering and growing uptake of its digital health solutions.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) owing to robust segmental performances and a rebound in non-COVID businesses.
Edwards Lifesciences (EW) at 52-Week High: What's Driving It?
by Zacks Equity Research
Robust performance across the Critical Care and TAVR businesses is driving the top line for Edwards Lifesciences (EW).
Thermo Fisher (TMO) Releases New Update for Omicron Detection
by Zacks Equity Research
Thermo Fisher's (TMO) TaqMan SARS-CoV-2 Mutation Panel currently offers direct identification of the novel variant of concern.
Medtronic (MDT) to Gain From Expanded Medicare Coverage for CGM
by Zacks Equity Research
CMS' expanded Medicare coverage includes continuous glucose monitors that can be integrated with Medtronic's (MDT) insulin pumps.
Exact Sciences (EXAS) Rides on Cologuard Sales Amid COVID Fear
by Zacks Equity Research
Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) better-than-expected third-quarter results and robust performances by its operating businesses.
Zimmer Biomet (ZBH) Americas Business Slows Down Amid Pandemic
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to face COVID-induced challenges and market pressure.
STERIS (STE) Plans Sale of Non-Core Arm for Debt Repayment
by Zacks Equity Research
The latest spin-off of STERIS' (STE) Renal Care business is expected to partly reduce the company's debt burden.
Is AMN Healthcare Services (AMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AMN Healthcare Services (AMN) and Apollo Endosurgery, Inc. (APEN) have performed compared to their sector so far this year.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) better-than-expected earnings in the fiscal second quarter and robust performance of the Diabetes arm.
Bruker (BRKR) Introduces JPK NanoWizard V for AFM Research
by Zacks Equity Research
Bruker's (BRKR) newly-introduced JPK NanoWizard V is expected to significantly contribute to life science atomic force microscopy investigations.
Here's Why You Should Hold on to Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Alcon's (ALC) better-than-expected third-quarter results and robust performance by the Vision Care arm.
Avantor (AVTR) to Improve Biopharma Supply Chain With New Site
by Zacks Equity Research
Avantor's (AVTR) new logistics hub in Westminster is intended to support growth of single-use businesses.